Insulin resistance: an atherothrombotic syndrome

Summary

The insulin resistance syndrome (IRS) is a clustering of atherothrombotic traits associated with increased vascular risk. We investigated the degree to which the phenotypic correlations between these traits are due to shared genetic and environmental factors.

A multivariate genetic analysis was performed in 537 adults from 89 healthy white north European families. All traits showed significant heritability. BMI had significant genetic correlations with fasting insulin, systolic blood pressure (sBP), plasminogen activator activator inhibitor-1 (PAI-1) and fibrinogen and triglyceride. Fasting insulin had a significant genetic correlation with fibrinogen and triglyceride and Factor VII (FVII). Significant genetic correlations were shown between triglyceride and PAI-1, fibrinogen and FVII. PAI-1 and tissue plasminogen activator (t-PA) showed significant genetic correlation with sBP and with each other. Pleiotropy was demonstrated between fibrino-gen and PAI-1, t-PA and FVII. Significant environmental correlations were also demonstrated.

This study demonstrates pleiotropy between coagulation and fibrinolytic factors. Shared genetic and environmental factors influencing haemostatic, metabolic and anthropometric traits underlie the atherothrombotic nature of the IRS.

Keywords

Pleiotropy - insulin resistance - haemostasis - genetics - families

• References

• 1 Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
• 2 Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key features of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-22.
• 3 Mitchell BD, Kammerer CM, Blangero J. et al. Genetic and environmental contributions to cardiovascular risk factors in Mexican Americans. The San Antonio Family Heart Study. Circulation 1996; 94: 2159-70.
• 4 Hsueh WC, Mitchell BD, Aburomia BA. et al. Diabetes in the Old Order Amish – Characterisation and heritability analysis of the Amish Family Diabetes Study. Diabetes Care 2000; 23: 595-601.
• 5 Xiang AH, Azen SP, Raffel LJ. et al. Evidence for joint genetic control of insulin sensitivity and systolic blood pressure in hispanic families with a hypertensive proband. Circulation 2001; 103: 78-83.
• 6 Snieder H, Boomsma DI, van Doornen LJ, Neale MC. Bivariate genetic analysis of fasting insulin and glucose levels. Genet Epidemiol 1999; 16: 426-46.
• 7 Edwards KL, Mahaney MC, Motulsky AG, Austin MA. Pleiotropic genetic effects on LDL size, plasma triglyceride, and HDL cholesterol in families. Arterioscler Thromb Vasc Biol 1999; 19: 2456-64.
• 8 Potter van Loon BJ, Kluft K, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993; 42: 945-9.
• 9 Landin K, Tengborn L, Smith U. Elevated fib-rinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227: 273-8.
• 10 Heywood DM, Mansfield MW, Grant PJ. Factor VII gene polymorphisms, factor VII: C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus. Thromb Haemost 1996; 75: 401-6.
• 11 Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normal and hypertriglyceridaemic men. Diabetologia 1993; 36: 817-25.
• 12 de Lange M, Sneider H, Ariens RAS, Spector TD, Grant PJ. The Genetics of Haemostasis: A Twin Study. Lancet 2001; 357: 101-5.
• 13 Souto JC, Almasy L, Borrell M. et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000; 101: 1546-51.
• 14 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematologica 1952; 17: 237-46.
• 15 Hasstedt SJ.. Pedigree Analysis Package v 4.0. (4.0). Salt Lake City, Utah: Department of Genetics; University of Utah; 1994
• 16 Hasstedt SJ. Variance components/major locus likelihood approximation for quantitative, polychotomous, and multivariate data. Genet Epidemiol 1993; 10: 145-58.
• 17 Lynch M, Walsh B. Genetics and analysis of quantitative traits. Sunderland, MA, USA: Sinauer Associates Inc; 1998
• 18 Harrap SB, Hopper JR. Genetics of haemosta-sis. Lancet 2001; 357: 83-4.
• 19 Mitchell BD, Kammerer CM, Mahaney MC. et al. Genetic analysis of the IRS. Pleiotropic effects of genes influencing insulin levels on lipoprotein and obesity measures. Arterioscler Thromb Vasc Biol 1996; 16: 281-8.
• 20 Edwards KL, Newman B, Mayer E, Selby JV, Krauss RM, Austin MA. Heritability of factors of the insulin resistance syndrome in women twins. Genet Epidemiol 1997; 14: 241-53.
• 21 Hong Y, Pedersen NL, Egberg N, de Faire U. Genetic effects for plasma factor VII levels independent of and in common with triglycerides. Thromb Haemost 1999; 81: 382-6.
• 22 Hong Y, Pedersen NL, Egberg N, de Faire U. Moderate genetic influences on plasma levels of plasminogen activator inhibitor-1 and evidence of genetic and environmental influences shared by plasminogen activator inhibitor-1, triglycerides, and body mass index. Arterioscler Thromb Vasc Biol 1995; 17: 2776-82.
• 23 Festa A, D’Agostino RJ, Mykkanen L. et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999; 19: 562-8.
• 24 Haffner SM, D’Agostino Jr. R, Mykkanen L. et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 562-8.
• 25 Poli KA, Tofler GH, Larson MG. et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 101: 264-9.
• 26 Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-60.
• 27 Dawson SJ, Winman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promotor of plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-45.
• 28 Behague I, Poirier O, Nicaud V. et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l’Infarctus du Myocarde. Circulation 1996; 93: 440-9.
• 29 Bernardi F, Marchetti G, Pinotti M. et al. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vasc Biol 1996; 16: 72-6.
• 30 Mennen LI, de Maat MP, Schouten EG. et al. Coagulation factor VII, serum-triglycerides and the R/Q353 polymorphism: differences between older men and women. Thromb Haemost 1997; 78: 984-6.
• 31 Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998; 18: 20-6.
• 32 Kohler HP, Mansfield MW, Clark PS, Grant PJ. Interaction between insulin resistance and factor XIII Val34Leu in patients with coronary artery disease. Thromb Haemost 1999; 82: 1202-3.
• 33 Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998; 62: 1198-211.
• 34 Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-8.
• 35 Kissebah AH, Sonnenberg GE, Myklebust J. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci 97 2000; 26: 14478-83.
• 36 Haverkate F, Thompson SG, Duckert F. Haemostasis Factors in Angina Pectoris; Relation to Gender, Age and Acute-phase Reaction. Results of the ECAT Angina Pectoris Study Group. Thromb Haemost 1995; 73: 561-7.
• 37 Bavenholm P, Proudler A, Silveira A, Crook D, Blomback M, de Faire U, Hamsten A. Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease. Thromb Haemost 1995; 73: 568-75.